High-throughput Drug Screening Identifies Ketotifen as a Potential Therapeutic Agent for Neuroendocrine Prostate Cancer
We performed a high-throughput drug screening and identified Ketotifen, originally an FDA-approved antidepressant, as candidate therapeutic agent for NEPC. RNA-seq was performed of LASCPC-01 cells treated with Ketotifen or PBS. Overall design: mRNA profiles of LASCPC-01 cells treated with PBS or Ketotifen